Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...
Under the planned partnership, Ginkgo and the Serbian Ministry of Science, Technological Development and Innovation will work to establish a Startup Accele...
ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Org...
GE HealthCare (Nasdaq: GEHC) today announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA)&mdash...
Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture,...
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fi...
AstraZeneca Foundation celebrates its 30th anniversary, the organization has awarded 12 nonprofit organizations $2,170,318 in grants across eight US states...
The protection of Kaneka's intellectual property stands as a paramount cornerstone of its business. Kaneka's commitment to safeguarding these rights is unw...
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% S...
“Our ongoing partnership with Bayer leverages the full suite of our Twist Biopharma Solutions offering of antibody discovery services to identify the...
Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of mu...
The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based o...
Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis advances strategy ...
© 2024 Biopharma Boardroom. All Rights Reserved.
